Announcement

Collapse
No announcement yet.

Company To Develop IC Treatment Based Upon Keay's Research

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • ICLori
    replied
    Woo hoo! It's about time someone paid attention to this research and tried to look into a treatment based on it!

    Thanks for posting this, Jill, this gives me more hope than just about anything I've read lately!

    Blessings,
    Lori

    Leave a comment:


  • Company To Develop IC Treatment Based Upon Keay's Research

    Editors Note- This is a very INTERESTING development. Dr. Susan Keay's research and discovery of the APF may now lead to a new therapeutic approach to IC. We've been expecting an announcement like this for the past several years and, apparently, Acologix has now agreed to develop the therapy. Fascinating and, honestly, the more companies interested in IC the better! - Jill

    ACOLOGIX LICENSES NOVEL TECHNOLOGY FOR TREATMENT
    OF INTERSTITIAL CYSTITIS FROM UNIVERSITY OF MARYLAND, BALTIMORE

    HAYWARD, Calif. – September 6, 2006 – Acologix, Inc., a privately-held biopharmaceutical company, announced today that it has licensed technology from the University of Maryland, Baltimore, for the potential treatment of interstitial cystitis (IC). A chronic bladder condition characterized by serious pain and increased frequency of urination, interstitial cystitis affects an estimated 700,000 Americans, of whom approximately 90 percent are women. To date, there are no satisfactory treatments for this condition.

    Acologix’ license includes patents related to Heparin Binding Epidermal Growth Factor-like Growth Factor (HB-EGF) and therapies targeting a novel human peptide known as anti-proliferative factor (APF). Research led by Susan Keay, M.D., Ph.D., Professor of Medicine, Division of Infectious Diseases, at the Baltimore VA Hospital and the University of Maryland, Baltimore, has demonstrated the potential of HB-EGF and APF in the development of a novel interstitial cystitis therapy. Acologix will sponsor continuing research and development efforts at the Baltimore VA and the University of Maryland, Baltimore.

    “Based on the ability of HB-EGF to normalize the physiology of bladder cells from IC patients, we believe it may represent a new way to treat interstitial cystitis,” said Dr. Keay.

    David Rosen, Ph.D., Senior Vice President of Research and Development at Acologix added, “Dr. Keay is a recognized leader in her field. We look forward to building on her research as we collaborate to develop a novel therapeutic for this debilitating condition.”

    About Acologix, Inc.

    Acologix, a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix is partnering with Toray Industries, Inc. of Japan on the development and commercialization of AC-820 (or TRK-820) for the treatment of uremic pruritus in dialysis patients. AC-820 is being studied in a European Phase 3 pivotal clinical trial, with a Phase 3 trial planned to launch in the United States. AC-100 (Dentonin®), a novel small peptide with dental, periodontal and orthopedic applications, has been studied in two recently concluded Phase 2 clinical studies, one in dental restoration procedures and another for the repair of periodontal defects, and further studies are planned. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and subsequent clinical problems associated with chronic kidney disease. For more information go to www.acologix.com.

    This press release contains “forward-looking” statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix’ business.
Working...
X